Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Bacteremia

Bacteremia

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Bacteremia

17 trials tracked for Bacteremia: 6 in phase 3 or 4 and 3 with published results. The most-cited published study has 439 citations.

17Trials tracked
6Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 3 Phase 3 3 Phase 2 5 Other / NA 6
  1. Phase 3 Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults Completed · 439 cited
  2. Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex Completed · 276 cited
  3. Phase 4 Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005) Completed · 56 cited
  4. Phase 4 Prophylactic Antimicrobial Catheter Lock Completed
  5. Phase 4 Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults Completed
  6. Phase 3 Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells Completed
Show 11 more trials
  1. Phase 2 Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients Completed
  2. Phase 2 Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection Completed
  3. Phase 2 Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia Completed
  4. Phase 2 Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029) Completed
  5. Phase 2 Antibiotic "Dysbiosis" in Preterm Infants Completed
  6. N/A Home Away From Home - Medical Outcomes Completed
  7. N/A Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures Completed
  8. N/A Hub Cleansing to Prevent Hub Infection Completed
  9. N/A Safety Evaluation of Seraph® 100 to Reduce Bacteremia in Patients on Hemodialysis Completed
  10. N/A A Cluster-randomized Cross-over Trial Evaluating the Comparative Effectiveness of Three Skin Antiseptic Interventions Completed
  11. N/A Rapid Blood Culture Identification Panel in Pediatric Patients in Guatemala Completed

Showing the 17 most-cited and recently-updated of 17 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Bacteremia: what the trials found

Clinical outcomes for specific agents in bacteremia include varying rates of success and safety profiles. Zavicefta (Ceftazidime-Avibactam) demonstrated a clinical cure rate of 59.3% in the mMITT analysis set and 66.7% at the end of treatment 3. Sulbactam was associated with significantly lower rates of nephrotoxicity compared to its comparator (12% vs. 32%, p=0.0002) in a population of patients with CRABC 6.

Safety data for Daptomycin indicates that approximately 40% of participants experienced post-baseline Creatine Phosphokinase (CPK) elevations above the upper limit of normal across several study arms 2. In studies evaluating device-related bacteremia, Heparin 1000U/mL was associated with a catheter clotting rate of 3.42% 4.

Vabomere showed an all-cause mortality rate of 4% in the mCRE-MITT population for patients with hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and bacteremia 5.

Recent results — preliminary, needs further review

  • AP-SA02 was evaluated for safety and tolerability; clinical improvement or response at day 12 was observed in various cohorts, with results ranging from 7 to 21 participants depending on the group 1.
  • Clinical improvement or response at 7 days after completion of antibiotic therapy was recorded for patients treated with AP-SA02 1.

For the clinician treating this condition

  • Sulbactam demonstrated a statistically significant reduction in nephrotoxicity compared to the comparator in CRABC patients 6.
  • Ceftazidime-Avibactam showed clinical cure rates between 59.3% and 66.7% in specific analysis sets 3.
  • Daptomycin is associated with CPK elevations in a significant portion of the patient population 2.

AI synthesis of 6 cited trials, updated Jun 19, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.